Invitae Stock Forecast, Price & News

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Invitae in the last twelve months. There are currently 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Invitae stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVTA, but not buy additional shares or sell existing shares.
View analyst ratings for Invitae or view top-rated stocks.

Wall Street analysts have given Invitae a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Invitae wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Invitae is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Invitae.

Invitae Co. (NYSE:NVTA) posted its quarterly earnings results on Tuesday, May, 4th. The medical research company reported ($0.63) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.60) by $0.03. The medical research company earned $103.60 million during the quarter, compared to analysts' expectations of $101.46 million. Invitae had a negative net margin of 194.99% and a negative trailing twelve-month return on equity of 31.82%. The business's revenue was up 61.2% compared to the same quarter last year. During the same period last year, the business earned ($1.03) EPS.
View Invitae's earnings history.

Invitae's stock was trading at $15.85 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NVTA shares have increased by 97.0% and is now trading at $31.22.
View which stocks have been most impacted by COVID-19.

9 Wall Street analysts have issued 12-month price targets for Invitae's stock. Their forecasts range from $30.00 to $58.00. On average, they expect Invitae's stock price to reach $42.50 in the next year. This suggests a possible upside of 36.1% from the stock's current price.
View analysts' price targets for Invitae or view top-rated stocks among Wall Street analysts.

59 employees have rated Invitae CEO Sean George on Glassdoor.com. Sean George has an approval rating of 87% among Invitae's employees.

Some companies that are related to Invitae include Quest Diagnostics (DGX), Guardant Health (GH), Natera (NTRA), CareDx (CDNA), Burning Rock Biotech (BNR), Veracyte (VCYT), Fulgent Genetics (FLGT), Castle Biosciences (CSTL), Genetron (GTH), RadNet (RDNT), DermTech (DMTK), Renalytix AI (RNLX), Personalis (PSNL), Celcuity (CELC) and Exagen (XGN).
View all of NVTA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Invitae investors own include NVIDIA (NVDA), Square (SQ), Roku (ROKU), Tesla (TSLA), Alibaba Group (BABA), The Trade Desk (TTD), Shopify (SHOP), salesforce.com (CRM), Advanced Micro Devices (AMD) and Okta (OKTA).

(NVTA) raised $76 million in an initial public offering on Thursday, February 12th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan acted as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

Invitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

Invitae's stock is owned by many different retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (12.00%), Nikko Asset Management Americas Inc. (6.90%), Sumitomo Mitsui Trust Holdings Inc. (6.89%), Gilder Gagnon Howe & Co. LLC (3.49%), Perceptive Advisors LLC (2.68%) and Redmile Group LLC (2.43%). Company insiders that own Invitae stock include E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Jason W Myers, Katherine Stueland, Kenneth D Knight, Randal W Scott, Robert F Werner, Robert L Nussbaum, Sean E George, Shelly D Guyer and Thomas Brida.
View institutional ownership trends for Invitae.

NVTA stock was sold by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Perceptive Advisors LLC, Victory Capital Management Inc., Redmile Group LLC, Capital Impact Advisors LLC, Man Group plc, Fred Alger Management LLC, and Franklin Resources Inc.. Company insiders that have sold Invitae company stock in the last year include E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Jason W Myers, Katherine Stueland, Kenneth D Knight, Robert F Werner, Robert L Nussbaum, Sean E George, Shelly D Guyer, and Thomas Brida.
View insider buying and selling activity for Invitae or view top insider-selling stocks.

NVTA stock was bought by a variety of institutional investors in the last quarter, including Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Suvretta Capital Management LLC, Sectoral Asset Management Inc, Price T Rowe Associates Inc. MD, Rock Springs Capital Management LP, Geode Capital Management LLC, and Alyeska Investment Group L.P..
View insider buying and selling activity for Invitae or or view top insider-buying stocks.

Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NVTA stock can currently be purchased for approximately $31.22.

Invitae has a market capitalization of $6.24 billion and generates $279.60 million in revenue each year. The medical research company earns $-602,170,000.00 in net income (profit) each year or ($2.78) on an earnings per share basis.

Invitae employs 2,100 workers across the globe.

The official website for Invitae is www.invitae.com.

Invitae is headquartered at 1400 16th Street, SAN FRANCISCO CA, 94103.

Invitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at 415-374-7782 or via email at [email protected]